Literature DB >> 28617574

Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.

Xuefang Ding1,2, Yujie Su1, Cheng Wang1, Fangrong Zhang1, Kerong Chen1, Yu Wang3, Min Li1, Wei Wang1.   

Abstract

Single-walled carbon nanotubes (SWNTs) with unique physicochemical properties have exhibited promising biomedical applications as drug and gene carriers. In this study, polyethylenimine (PEI)-modified SWNT conjugates linked with candesartan (CD) were developed to deliver vascular endothelial growth factor (VEGF)-targeted siRNA (siVEGF) for the synergistic and targeted treatment of tumor angiogenesis. The characterization results revealed that SWNT-PEI-CD conjugates were successfully synthesized and exhibited desirable dispersibility and superior stability. Confocal laser scanning microscopy (CLSM) and flow cytometry (FCM) results showed that SWNT-PEI-CD/siVEGF complexes could achieve high cellular uptake and specific intracellular distribution of siRNA in AT1R overexpressed PANC-1 cells. Strong down-regulation of VEGF was also verified by qualitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blot in complex-treated PANC-1 cells. The in vitro angiogenesis assay showed that SWNT-PEI-CD/siVEGF complexes highly inhibited tube formation of human umbilical vein endothelial cells. Furthermore, in vivo observation in PANC-1 xenografted nude mice demonstrated that SWNT-PEI-CD/siVEGF complexes exhibited significant distribution at tumor sites and caused obvious inhibition of tumor growth and tumor-associated angiogenesis repression induced by the drug combination of CD and siVEGF. Finally, a WST-1 assay indicated that SWNT-PEI-CD possessed low cytotoxicity, and a hemolysis test showed good biocompatibility of SWNT-PEI-CD. Hematological and histological analyses confirmed that SWNT-PEI-CD/siVEGF complexes did not cause any obvious toxic effects to blood and major organs. These findings suggested that the SWNT-PEI-CD/siVEGF co-delivery system with tumor-targeting specificity, improved endosomal escaping properties, and collaboration of angiogenesis inhibition could be a prospective method for efficient tumor antiangiogenic therapy.

Entities:  

Keywords:  VEGF-targeted siRNA; candesartan; single-walled carbon nanotubes; synergistic inhibition; tumor angiogenesis

Mesh:

Substances:

Year:  2017        PMID: 28617574     DOI: 10.1021/acsami.7b04971

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  11 in total

1.  Candesartan induces tumor vascular normalization to improve the efficacy of radiotherapy in the therapeutic window.

Authors:  Fei Zhu; Wendong Yao; Yanjun Huang; Yanhong Chen; Zeng Wang; Xinjun Cai
Journal:  Ann Transl Med       Date:  2022-05

Review 2.  Nanotechnology for angiogenesis: opportunities and challenges.

Authors:  Saeid Kargozar; Francesco Baino; Sepideh Hamzehlou; Michael R Hamblin; Masoud Mozafari
Journal:  Chem Soc Rev       Date:  2020-06-15       Impact factor: 54.564

Review 3.  Regulation of cellular gene expression by nanomaterials.

Authors:  Sang Hun Chun; Ji Soo Yuk; Soong Ho Um
Journal:  Nano Converg       Date:  2018-11-30

4.  Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect via Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment.

Authors:  Fang Li; Yu Wang; Wei-Liang Chen; Dan-Dan Wang; Ye-Juan Zhou; Ben-Gang You; Yang Liu; Chen-Xi Qu; Shu-di Yang; Meng-Tian Chen; Xue-Nong Zhang
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556

Review 5.  Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.

Authors:  Zhengyang Yang; Wei Deng; Xiao Zhang; Yongbo An; Yishan Liu; Hongwei Yao; Zhongtao Zhang
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

Review 6.  Recent advances of nanotechnology-based tumor vessel-targeting strategies.

Authors:  Dongjie Zhu; Yang Li; Zhengjia Zhang; Zeyu Xue; Zhenglai Hua; Xinyi Luo; Ting Zhao; Cheng Lu; Yuanyan Liu
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

7.  Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy.

Authors:  Yu Xia; Changbing Wang; Tiantian Xu; Yinghua Li; Min Guo; Zhengfang Lin; Mingqi Zhao; Bing Zhu
Journal:  RSC Adv       Date:  2018-01-09       Impact factor: 3.361

8.  Rules of Chinese Herbal Intervention of Radiation Pneumonia Based on Network Pharmacology and Data Mining.

Authors:  Wenchao Dan; Cong Wu; Chunyan Xue; Jinlei Liu; Xinyuan Guo; Yanjie Lian
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-25       Impact factor: 2.650

9.  Co-Delivery of Repurposing Itraconazole and VEGF siRNA by Composite Nanoparticulate System for Collaborative Anti-Angiogenesis and Anti-Tumor Efficacy against Breast Cancer.

Authors:  Mingji Jin; Bowen Zeng; Yanhong Liu; Lili Jin; Yan Hou; Chao Liu; Wei Liu; Hao Wu; Liqing Chen; Zhonggao Gao; Wei Huang
Journal:  Pharmaceutics       Date:  2022-06-28       Impact factor: 6.525

Review 10.  Bench-to-Bedside in Vascular Medicine: Optimizing the Translational Pipeline for Patients With Peripheral Artery Disease.

Authors:  Tom Alsaigh; Belinda A Di Bartolo; Jocelyne Mulangala; Gemma A Figtree; Nicholas J Leeper
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.